The authors would like to correct the following errors: on page 64; paragraph 1, "RTG doses for treatment of early-stage PD monotherapy range from 2 mg/24 hours to 6 mg/24 hours, with recommended titration of 2 mg/24 hours weekly. 5 For adjunct therapy in advanced-stage PD, RTG may be started at 4 mg/24 hour period and titrated up weekly by an additional 2 mg/24 hour period, with a maximum recom mended dose of 16 mg/24 hours.
7 " should be "RTG doses for treatment of early-stage PD monotherapy range from 2 mg/24 hours to 8 mg/24 hours (2-6 mg/24 hours in the US), with recommended titration of 2 mg/24 hours weekly. 5 For adjunct therapy in advanced-stage PD, RTG may be started at 4 mg/24 hour period and titrated up weekly by an additional 2 mg/24 hour period, with a maximum recom mended dose of 16 mg/24 hours (4-8 mg/24 hours in the US).
5 "
On page 64; paragraph 5, "The mean RTG dose was 8 mg/24 hours, while the mean ropinirole dose was 14.1 mg/day." should have been "The majority of patients (92%) received RTG maintenance dose of 8 mg/24 h, while the median ropinirole dose was 14.1 mg/day."
On page 64; paragraph 6, "Three hundred and forty-one patients were randomized to receive RTG 8 mg/24 hours, 12 mg/24 hours, or placebo for 28 weeks." should have been "Three hundred and forty-one patients were randomized to receive RTG up to 8 mg/24 hours, up to 12 mg/24 hours, or placebo for 28 weeks."
On page 65; Table 1 , data in the Doses column and the Notes section have been updated. a A mean dose of rTg in the treatment group was reported as 2.1 mg/24 hours; b RTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information 5 ), ie, 1.125 mg is equivalent to 0.5 mg/24 h, 2.25 mg to 1 mg/24 h, and 4.5 mg to 2 mg/24 h. Abbreviations: RTG, rotigotine; RLS, restless legs syndrome; SD, standard deviation; IRLS, International Restless Legs Syndrome Study Group severity rating scale; CGI-1, Clinical Global Impressions item-1; PSQI, Pittsburgh Sleep Quality Index; Plo, placebo.
On page 66; paragraph 2, "In an open-label study, advanced-PD patients were treated with levodopa, pramipexole (,1.5 mg/day), or ropinirole (,6.0 mg/day), and RTG (,8 mg/24 hours) for an 8-week treatment period.
7 " should have been "In an open-label study, advanced-PD patients were treated with levodopa, pramipexole (#1.5 mg/day), or ropinirole (#6.0 mg/day), and RTG (#8 mg/24 hours) for an 8-week treatment period.
7"
On page 68; Table 3 , data in the Study, doses column for the Stiasny-Kolster study and the Notes section have been updated. a RTG content per system (mg) originally reported; RTG nominal doses (mg/24 h) were calculated using a ratio of 2.25 (as per US prescribing information 5 ), ie, 4.5 mg is equivalent to 2 mg/24 h, 9 mg to 4 mg/24 h, 13.5 mg to 6 mg/24 h, and 18 mg to 8 mg/24 h; b The mean (SD) dose was 5.7 (0.84) mg/24 h; 6 mg dose for majority of participants; c Ninety-two percent of those in the RTG group were treated with this dose in the maintenance phase and 8% had lower doses; there was no SD reported for UPDRS II or III separately; however, the combined UPDRS part III + part II scores were significantly more improved compared to placebo at the end of the maintenance phase (P,0.0001); d there was no SD reported for UPDRS II or III separately, however the combined UPDRS part III + part II scores were significantly more improved compared to placebo at the end of the maintenance phase (P,0.0001). Abbreviations: RTG, rotigotine; PD, Parkinson's disease; UPDRS II, Unified Parkinson's Disease Rating Scale part II (activities of daily living); UPDRS III, Unified Parkinson's. Disease Rating Scale part III (motor examination); Plo, placebo.
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